Skip to main content
. Author manuscript; available in PMC: 2018 Dec 12.
Published in final edited form as: Leukemia. 2018 Mar 29;32(12):2626–2635. doi: 10.1038/s41375-018-0116-y

Figure 4. Added value of lincRNA signature on known clinical risk features for OS.

Figure 4

a) MRD alone, MRD- separated by lincRNA signature and MRD+ separated by lincRNA signature b) ISS alone, ISS 1 and ISS 2/3 separated by lincRNA signature c) Cytogenetic risk groups (del17p, t(4;14) and t(14;16) alone, Standard risk and high-risk separated by lincRNA signature respectively)